Trial Profile
Phase 2 trial of gemcitabine And carboplatin followed by epstein-barr virus-specific autologous cytotoxic T lymphocytes in the patients with Nasopharyngeal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2018
Price :
$35
*
At a glance
- Drugs Rovaleucel (Primary) ; Carboplatin; Gemcitabine
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 09 Feb 2018 New trial record
- 05 Feb 2018 Results published in a Tessa Therapeutics Media Release.